MoneyWeek's comprehensive guide to the best of this week's share tips from the rest of the UK's financial pages.
Three to buy
Renalytix AI
The Mail on Sunday
The travails of Neil Woodford's fund highlight the dangers of investing in early-stage healthcare businesses, but the sector still has promise. This Aim-listed group helps with early diagnosis of kidney disease, which affects more than 850 million people worldwide. Its KidneyIntelX diagnostic system uses a simple blood test to determine which patients are most at risk of developing advanced kidney problems. Revenues should soar in coming years and city brokers have "high hopes". 240p
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Chemring
This defence contractor produces countermeasures such as flares, decoys and "chaff" to help jet fighters evade detection. Its also offers cybersecurity and produces equipment to detect chemical, biological and explosive threats. A "heavyweight" management team boosted the order book by a third in the first half. Shareholders have been "put through the wringer" of late, but things are looking up. 170p
CYBG
Clydesdale and Yorkshire Banking Group is one of the few challengers to have made a dent in the banking sector. A "chunky" £61bn mortgage book gives it scale, which was enhanced by last year's £1.7bn acquisition of Virgin Money. The purchase of a well-known brand is a "huge boost" to efforts to draw in more customers. Integration risks and shrinking margins in the UK mortgage market are key risks, but with shares trading below book value and £150m in cost savings anticipated from the Virgin deal, this stock is a buy. 179p
Three to sell
Codemasters
Shares in this video games developer have surged almost 40% since the end of November but it is now time to take profits. A deal with Chinese giant NetEase has opened access to the Middle Kingdom's vast gaming market. Full-year revenue growth of 12% is impressive, but if you strip out the NetEase venture it becomes a pedestrian 3%. Recent good news is now in the price and, with the financial benefits unlikely to start flowing until 2020 or 2021, the "news vacuum" could cause share-price volatility. 251p
J Sainsbury
The failure of Sainsbury's proposed deal with Asda has given the shares downward momentum. All of the big four supermarkets (the others are Asda, Tesco and Wm Morrison) have been losing market share to discounters Aldi and Lidl, but none more so than Sainsbury. Unfortunately, management has not responded to the failed merger plan with the required boldness and its determination to reduce debt levels will constrict capital expenditure, which will do nothing to reverse recent declines in market share and margins. 202p
Just Eat
Just Eat's share price has been "suffering a bout of indigestion". Amazon's investment in arch-rival Deliveroo has put the spotlight on ferocious competition in the sector. Just Eat has responded by offering steep discounts and investing in a new delivery network but this is a low-margin business and the final bill is uncertain. On 31.5 times forecast earnings and with no dividend the shares do not look appetising. 621p
...and the rest
The Daily Telegraph
Paris-listed cognac maker Rmy Cointreau has been around since 1724 and remains under family control. This recipe for longevity looks cheap (€119.80).
Investors Chronicle
Metrology specialist Renishaw has been hit by the slowdown in China but a strong balance sheet and high margins mark this out as a quality business buy (3,908p). Countryside Properties has been buffeted by souring sentiment towards housebuilders and a connection with Neil Woodford's Equity Income Fund, but with the shares on just seven times forward earnings there could be re-rating potential when the "shadow of Woodford lifts" (296.5p). Fewer contract wins and rising debt could drive housing services provider Mears Group towards a "tipping point" sell (255p).
Mail on Sunday
Wales-based Creo Medical is a pioneer in stomach cancer treatment. It is loss-making, but long-term prospects are bright (194p).
Shares
Fears of slower global growth have driven shares in cruise ship operator Carnival down too far. It is a high-quality operator that has delivered £7.6bn to shareholders through dividends and buybacks since 2014 buy (3,935p). News of record revenue and profit have sent shares in electronics equipment maker Halma to an all-time high buy on any dips (1,941p). Premium lifestyle brand Joules continues to "confound" retail sector doom and gloom and has exciting global growth potential (279p).
The Times
"Remarkable" sales figures from Gregg's show that investors underestimate the baker at their peril (2,234p).
A German view
Denmark's Ambu is a hidden gem, says Der Aktionaer. Few have heard of the 53-year-old company, but its products can be found in operating theatres around the world. Offerings range from face masks and breathing bags to endoscopes and electrodes used in electrocardiograms (ECGs). The long-term outlook for medical devices is encouraging and Ambu has just announced a record quarter: sales jumped by 14% to €105m as operating earnings reached €26m. The group's promising product pipeline includes new endoscopes, which should allow it to reach its sales target of 750,000 devices by the end of the year. A recent dip in the share price is a good buying opportunity for long-term investors.
IPO watch
Airtel, Africa's second-largest mobile network operator after MTN, will float in London at the end of June. The group will have a free float of at least 25% of the equity and the price range for the initial public offering (IPO) will be 80p-100p, implying a market capitalisation of £3bn-£3.6bn. That is the sort of market value associated with mid caps in the FTSE 250 Index. Airtel, which has its headquarters in the Netherlands, will list in Nigeria at the same time. The telecoms and mobile money transfer company operates in 14 African countries and has nearly 100 million subscribers. It is owned by India's Bharti Aitel International.
-
Will the Bitcoin price hit $100,000?With Bitcoin prices trading just below $100,000, we explore whether the cryptocurrency can hit the milestone.
-
Inheritance tax receipts jump 11% even before Autumn Budget overhaulOfficial figures show inheritance tax receipts are rising even before the chancellor’s changes to reliefs
-
Carnival faces a long road to recovery – avoid for nowTips Cruise operator Carnival suffered heavily during the pandemic, losing 90% of its market value and burning through $7bn in cash. Sales are back on the rise, but the company continues to struggle, says Rupert Hargreaves.
-
Neil Woodford’s back – but has he really learned anything?Opinion Disgraced fund manager Neil Woodford is planning a comeback. But he doesn’t seem to have learned much from his many mistakes. So why would anyone invest with him now?
-
Neil Woodford’s back – but sometimes sorry isn’t enoughAdvice Neil Woodford’s funds blew up in 2019. Now he is on the comeback trail. But his apologies are unconvincing.
-
Woodford investor? Your first payment is coming soonNews Private investors left stranded by the collapse of the Woodford Equity Income fund will soon be getting at least some of their money back. But they will have to wait a while longer to see how much more – if any – they will receive.
-
Neil Woodford continues to cast a shadow over his successor at InvescoFeatures Mark Barnett, former star manager Neil Woodford’s successor at Invesco, has applied the same formula, and is struggling.
-
Is it time to buy Patient Capital Trust?Features Neil Woodford’s Patient Capital Trust has been taken over by asset manager Schroders. The share price has surged - but should you buy in? John Stepek looks at the trust’s prospects.
-
Neil Woodford: no silver lining for his investorsEditor's letter Neil Woodford made every mistake it is possible to make as a money manager. And his investors have been stiffed. But however wrong it all went, Woodford never stopped taking the fees.
-
Woodford believed his own hype – now his investors are paying the priceFeatures Neil Woodford was once one of the brightest stars in Britain’s investment firmament. Then he came crashing down to earth. John Stepek explains what went wrong.
